ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2070

Co-morbidities in Patients with OA and RA: Results from a Large US Rheumatic Disease Registry

Sofia Pedro1, Rebecca Schumacher 1, Alyssa Dominique 2, Yomei Shaw 1, Kristin Wipfler 1 and Kaleb Michaud 3, 1FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, 2Bristol-Myers Squibb, Princeton, NJ, 3FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Comorbidity, OA, rheumatoid arthritis (RA) and registry

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The burden of co-morbid conditions can impact the overall quality of life in patients with RA and OA. However, the presence of common co-morbidities in inflammatory and degenerative arthritis is not well described. We sought to compare overlapping co-morbidities in the two patient groups.

Methods: We identified patients with physician-diagnosed OA and RA in FORWARD, The National Databank for Rheumatic Diseases, a large US registry with comprehensive 6-month questionnaires from 1998 through 2018, with patients primarily recruited through rheumatology clinics. Each patient with OA was age- and sex-matched to two patients with RA at study entry. We compared demographics, clinical characteristics and current and past co-morbidities between the OA and RA groups. Patient status at the last observation was further categorized as active (if they had a full follow-up questionnaire collected in the last 2 years), not active, or lost to follow-up/deceased. T-tests and Chi-square tests were used as appropriate to assess differences.

Results: Overall, 9463 patients with OA were matched to 18,926 patients with RA. Patients with OA experienced more pain compared with patients with RA (4.6 vs 4.2), but patients with RA had slightly worse HAQ scores (1.0 vs 1.1; Table 1). Higher use of NSAIDs was reported for patients with OA. Except for pulmonary and liver disorders, which were more prevalent among patients with RA, patients with OA had a higher prevalence of the majority of co-morbidities, with an average overall disease co-morbidity index of 2.3 vs 2.1 for patients with RA. Presence of overlapping autoimmune disease was also higher for patients with OA (OA vs RA: 8.4% vs 3.1%). The most frequently reported co-morbidities (OA vs RA) were hypertension (69% vs 66%), gastrointestinal disorders (67% vs 63%) and psychiatric disorders (55% vs 48%) (Figure 1). As expected, patients who were lost to follow-up/deceased had worse outcomes and more co-morbidities than active and non-active patients both with OA and RA. Patients who were not active had more co-morbidities than active patients, revealing an informative drop-out (Table 2).

Conclusion: Patients with OA reported more overlapping co-morbidities than patients with RA, even after age- and sex-matching. Although RA has a much more complex etiology, affecting more organ systems, our data suggest that the burden of having OA in terms of overlapping symptoms and other problems is not negligible in comparison. It is possible that the advancement of medications for RA has aided in lessening the burden of disease or other co-morbidities when compared with OA. Also, this OA cohort may have increased disease severity due to seeking care from a rheumatologist.

Professional medical writing: Katerina Kumpan, Caudex, funded by Bristol-Myers Squibb.


Disclosure: S. Pedro, FORWARD, the National Data Bank for Rheumatic Disease, 3, FORWARD, The National Data Bank for Rheumatic Diseases, 3; R. Schumacher, None; A. Dominique, Bristol-Myers Squibb, 1, 3, 4; Y. Shaw, Amgen, 2, MSD, 2, 8; K. Wipfler, Option Care, 3; K. Michaud, Pfizer, 2, Rheumatology Research Foundation, 2.

To cite this abstract in AMA style:

Pedro S, Schumacher R, Dominique A, Shaw Y, Wipfler K, Michaud K. Co-morbidities in Patients with OA and RA: Results from a Large US Rheumatic Disease Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/co-morbidities-in-patients-with-oa-and-ra-results-from-a-large-us-rheumatic-disease-registry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/co-morbidities-in-patients-with-oa-and-ra-results-from-a-large-us-rheumatic-disease-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology